RADIATION
definitive radiotherapy
Participants were treated with definitive thoracic radiotherapy
Status
Active, not recruiting
Phase
Phase 2
Enrollment
114
Locations
1
Results
Not posted
Publications
9
Study summary
This prospective phase II randomized study is to determine the impact of thymosin alpha-1 on the concurrent chemoradiotherpay followed by immunotherapy consolidation in patients with locally advanced NSCLC by assessing the survival outcomes, treatment responses and toxicities.
This prospective phase II randomized study is to determine the impact of thymosin alpha-1 on the concurrent chemoradiotherpay followed by immunotherapy consolidation in patients with locally advanced NSCLC by assessing the survival outcomes, treatment responses and toxicities. Patients with locally advanced NSCLC who will receive concurrent radiochemotherapy followed by immunotherapy consolidation will be randomly divided into two groups (concurrent Tα1 treatment group and control group \[in which Tα1 will not be used\]), and the overall survivals, progression-free survivals (PFS), completion rate of immunotherapy consolidation, toxicities/adverse effects, and peripheral blood immune biomarkers will be compared between these two groups.
Interventions
RADIATION
Participants were treated with definitive thoracic radiotherapy
DRUG
All participants receive two cycles of albumin-bound paclitaxel (260mg/m2) on d1 and cisplatin (25mg/m2) from d1 to d3 in combination with tislelizumab (200mg) on d1.
DRUG
Concurrent chemotherapy consists of weekly albumin-bound paclitaxel (50mg/m2) and cisplatin (25mg/m2).
DRUG
Participants without disease progression, grade ≥3 toxicities, and/or grade ≥2 pneumonitis after CCRT receive tislelizumab 200 mg (Q3W) for up to 12 months.
DRUG
Participants in the Tα1 treatment group will receive Tα1 from the beginning of induction chemo-immunotherapy until the completion of immunotherapy consolidation. In detail, Tα-1 would be administered according to the following three stages: 1. Induction chemo-immunotherapy: Tα-1 will be subcutaneously administered at 4.8 mg on d1 and d3 for each cycle. 2. Concurrent chemoradiotherapy: Tα-1 will be subcutaneously administered at 4.8mg biweekly. 3. Immunotherpay consolidation: Tα-1 will be administered concurrently with tislelizumab at 4.8mg (Q3W) for up to 12 months.
Timeline
First posted
Nov 18, 2023
Study start
Jul 25, 2023
Primary completion
Aug 30, 2026
Study completion
Aug 30, 2026
Results posted
Not reported
Registry updated
Nov 17, 2025
Outcomes
Completion rate of immunotherapy
Time frame · Calculated from the start of treatment to one year after the last treatment completion
Proportion of participants completing 12 months of consolidation of immutherapy
Overall survival
Time frame · 2 years
Progression-free survival
Time frame · one year
Incidence of ≥grade 2 pneumonia
Time frame · through study completion, an average of 1 year
Drop-out rate during the I/O consolidation
Time frame · One year
The absolute count of total lymphocyte in peripheral blood
Time frame · Calculated from the start of treatment to one year after the last treatment completion; up to 18 months
Measured at baseline, before immunotherapy, and every 3-4 months thereafter until the end of immunotherapy.
The expression of peripheral blood cytokines (including IL2, IL4, IL6, IL10, TNF-α, and IFN-γ)
Time frame · Calculated from the start of treatment to one year after the last treatment completion; up to 18 months
Measured at baseline, before immunotherapy, and every 3-4 months thereafter until the end of immunotherapy.
The absolute count of peripheral blood lymphocyte subsets (including CD3+, CD3+CD4+, CD3+CD8+, CD19+, CD3-CD16+CD56+, and CD56+ NK cells, PD-1+CD8+ T cells, Tim3+ CD8+ T cells, CD62lowCD4+ T cells, PD-1+CD4+ T cells, and Tim3+CD4+ T cells
Time frame · Calculated from the start of treatment to one year after the last treatment completion; up to 18 months
Measured at baseline, before immunotherapy, and every 3-4 months thereafter until the end of immunotherapy.
Eligibility
Inclusion Criteria: * aged ≥18 years old * histologically confirmed locally advanced and unresectable NSCLC; * no prior radiotherapy or surgery; * with the life expectancy over 12 weeks; * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1; * adequate bone marrow and hepatic and renal functions; * informed consent Exclusion Criteria: * Concurrent enrollment in another clinical trial, unless it is an observational (non-interventional) clinical study; * With histologically documented combined small-cell lung carcinoma; * Major surgery (excluding vascular access placement) within 4 weeks prior to enrollment in the study; * Active or prior documented autoimmune disease within the past 2 years; * Active or prior documented inflammatory bowel disease (eg, Crohn's disease, ulcerative colitis); * History of innate immunodeficiency; * History of organ transplant that requires the use of immunosuppressives; * A mean heart rate-corrected QT interval (QTc) ≥ 470 ms, calculated using Bazett correction from 3 ECG calculation cycles; * Poorly managed health conditions that include but are not limited to persistent or active infections, symptomatic congestive heart failure, poorly controlled hypertension, unstable angina, arrhythmia, active peptic ulcer disease or gastritis, active hemorrhagic diseases, hepatitis C or human immunodeficiency virus (HIV) infection, hepatitis B (positive HBsAg and HBV DNA \> 500 IU/ml), and mental disorders/social conditions that may hinder the compliance with the study requirements or the ability to give written informed consent willingly; * Active tuberculosis; * Receipt of live or attenuated vaccination within 30 days prior to the first dose of the investigational agents; * History of another primary malignancy within the past 5 years, excluding adequately treated basal or squamous cell skin cancers or cervical carcinoma in situ; * Pregnant/breastfeeding women or males/females of reproductive potential who do not use contraception.
Study locations
China. Showing up to 24 locations stored in the fast local snapshot.
Sun yat-sen university cancer center
Guangzhou, Guangdong, China
Publications
Related trials
The Methodist Hospital Research Institute · Vaccine Response · COVID-19 Vaccine
Phase 1
Recruiting
75
2026-07
Fakih IVF Fertility Center · Recurrent Implantation Faliure
Phase 2 / Phase 3
Recruiting
136
2026-06
Beijing Friendship Hospital · Colorectal Neoplasms
Not applicable
Completed
47
2026-06
Sun Yat-sen University · Melanoma · Immune-related Adverse Event
Phase 2
Recruiting
55
2026-06
Fudan University · Esophageal Squamous Cell Carcinoma
Not applicable
Active, not recruiting
50
2026-04
William B. Ershler, MD · COVID-19
Phase 2
Completed
189
2026-04
The First Affiliated Hospital with Nanjing Medical University · Gastric Cancer
Phase 2
Recruiting
48
2026-03
Zekuan Xu · Gastric Cancer · Esophagogastric Junction Adenocarcinoma
Phase 2
Recruiting
30
2026-03
Related PeptideStat pages
Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.